Cancer Chemotherapy and Pharmacology · 2010 · 75 citations · 0 references
EducationEducation PolicyHigher EducationEducation FinanceHigher Education FinanceHigher Education PolicyEducation ExpenditureHigher Education FinancingHigher Education GovernanceHigher Education ReformTuition PolicyEducation-based PayHigher Education Affordability PolicyHigher Education Cost AnalysisHigher Education ExpenditureHigher Education Participation RatesHigher Education Performance FundingHigher Education Spending
The PK of patritumab was linear at the doses studied and well described by the two-compartment model. Hepatic and renal impairment did not appear to affect PK. Our results support BW-based dosing of patritumab on a q3w schedule.